Newswire:

News chronological report by our AI freelance journalists with an independent and neutral analysis from worldwide and local news sources. Expanded coverage of different viewpoints grouped by topics. View more → Latest Newswires

Health:
Trial | Heart View latest Live

Boehringer's Survodutide Passes Cardiovascular Safety Obesity Trial Phase Three

12 articles from 5 sources in 5 cities of 2 countries for the past 3 days First reported by 'The Pharma Letter'

Claude:

Boehringer Ingelheim's survodutide met cardiovascular safety goals in Phase III obesity trials, advancing regulatory filing plans. Lower LDL targets reduced heart disease risk more than initial drug choice. A heart-failure drug showed preliminary promise for fewer AFib recurrences post-ablation. Yoga improved quality of life in heart-failure patients but didn't reduce deaths. Left bundle branch pacing cut combined heart failure and death risk by 59%. Stopping statins increased heart attacks ... - according to Erudite News

Claude:

Related coverage: Trial | Heart

2026-11-10 10:49

German pharma company Boehringer Ingelheim said survodutide has met the cardiovascular safety objective of a Phase III trial in people with obesity or overweight, supporting plans to seek regulatory …

The Pharma Letter |

Survodutide meets heart safety goal as Boehringer plans obesity filings

2026-11-10 07:18

In the Ez-PAVE trial, heart patients who began statin-ezetimibe therapy had similar three-year cardiovascular event rates to those who started with a statin alone, while lower LDL targets reduced …

Medical Daily |

For heart patients, hitting a very low LDL target mattered more than starting with one cholesterol drug or two in the Ez-PAVE trial

2026-11-10 07:05

A 320-patient randomized trial from China found fewer atrial fibrillation recurrences after ablation among patients taking sacubitril-valsartan, but the preliminary findings have not undergone peer …

Medical Daily |

A heart-failure drug was linked to fewer irregular-rhythm recurrences after AFib ablation— but the evidence is still preliminary

2026-11-10 05:17

A large Indian trial found structured yoga improved quality of life and six-minute walking distance for people with heart failure, but did not significantly reduce deaths, hospitalizations or strokes.

Medical Daily |

Yoga helped people with heart failure feel better and walk farther— but did not reduce deaths or hospital stays in a large India trial

2026-11-10 04:30

In the OptimPacing trial, left bundle branch pacing reduced a combined risk of death, heart failure hospitalization and pacing-induced cardiomyopathy versus standard right ventricular pacing, with …

Medical Daily |

A pacemaker technique using the heart's natural electrical wiring cut the combined risk of heart failure, death or pacing-related heart …

2026-11-10 04:25

The STREAM trial found that older adults who stopped statins had similar average time free of major cardiovascular events, but higher rates of heart attacks, strokes and death than those who …

Medical Daily |

Stopping statins met the STREAM trial's main test, but more older adults had heart attacks, strokes or died

2026-11-10 01:21

In the seven-year Lp(a)HORIZON trial, pelacarsen sharply reduced Lp(a) levels but did not prevent heart attacks, strokes, urgent artery procedures or cardiovascular deaths.

Medical Daily |

A drug cut Lp(a) by 78%— but did not reduce heart attacks, strokes or cardiovascular deaths in a seven-year trial

2026-11-09 21:47

Here are today's health headlines: A drug targets two cholesterol problems, a surprising heart disease medication trial and no-shave November tips.

First Coast News |

Daily Dose: One shot targets two cholesterol problems, a surprising heart disease drug trial result and no-shave November tips

2026-11-09 20:02

CHICAGO — AI-interpreted transthoracic echocardiography reports were noninferior to human interpretations and may substantially cut reading time, according to results of the AI ECHO INSIGHT trial. …

Healio |

AI-interpreted echocardiograms comparable to human reports, may halve reading time

2026-11-09 18:44

CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported at the American …

Healio |

ANGPTL4 inhibition appears to reduce triglycerides

2026-11-09 15:09

A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels …

News Medical |

New monoclonal antibody therapy significantly lowers patient triglyceride levels

2026-11-09 12:01

Novartis' Lp(a)-lowering drug pelacarsen reduced lipoprotein(a) by 78% but did not lower the risk of major cardiovascular events in the Phase III Lp(a) HORIZON trial, according to results presented …

The Pharma Letter |

Pelacarsen cuts Lp(a) by 78% but not cardiovascular events in Phase III HORIZON trial

Latest Newswires

AI Reports Summaries

Search - My Filters

Guided Tour

0 Favorites	0 Likes
0 Comments	0 Dislikes